C07K 16/4241
Against anti-human or anti-animal ig
Official title: {against anti-human or anti-animal Ig}
C07K16/4241 (Against anti-human or anti-animal ig) appears on 363 US grants and 383 published applications in this corpus.
Search patents in C07K- Granted patents
- 363
- Published applications
- 383
- Assignees
- 222
- Inventors
- 841
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 3 | 0 |
| 1988 | 2 | 0 |
| 1989 | 6 | 0 |
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 11 | 0 |
| 1993 | 12 | 0 |
| 1994 | 10 | 0 |
| 1995 | 11 | 0 |
| 1996 | 12 | 0 |
| 1997 | 13 | 0 |
| 1998 | 16 | 0 |
| 1999 | 19 | 0 |
| 2000 | 9 | 0 |
| 2001 | 17 | 3 |
| 2002 | 14 | 17 |
| 2003 | 9 | 16 |
| 2004 | 4 | 8 |
| 2005 | 8 | 20 |
| 2006 | 4 | 14 |
| 2007 | 8 | 14 |
| 2008 | 7 | 17 |
| 2009 | 10 | 16 |
| 2010 | 6 | 15 |
| 2011 | 7 | 10 |
| 2012 | 11 | 14 |
| 2013 | 13 | 10 |
| 2014 | 5 | 18 |
| 2015 | 8 | 14 |
| 2016 | 6 | 22 |
| 2017 | 14 | 16 |
| 2018 | 8 | 12 |
| 2019 | 8 | 11 |
| 2020 | 11 | 18 |
| 2021 | 7 | 20 |
| 2022 | 7 | 15 |
| 2023 | 7 | 16 |
| 2024 | 10 | 13 |
| 2025 | 13 | 24 |
| 2026 | 11 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof11 Aug 2026US 12,703,762 B2Novartis AG
- Anti-vedolizumab antibodies and uses thereof28 Jul 2026US 12,693,298 B1Takeda Pharmaceutical Company Limited
- Modular platform for targeted therapeutics30 Jun 2026US 12,668,643 B2Ramot at Tel-Aviv University Ltd.
- Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity23 Jun 2026US 12,662,552 B2Chugai Seiyaku Kabushiki Kaisha
- Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy16 Jun 2026US 12,653,872 B2AC Immune SA
- Lysosome-Mediated Degradation of Extracellular Proteins16 Jul 2026US 2026/0199495 A1Washington University
- Humanized anti-acth antibodies and use thereof9 Jul 2026US 2026/0193344 A1H. Lundbeck A.S.
- Anti-idiotype antibodies and uses thereof2 Jul 2026US 2026/0184818 A1Mediterranea Theranostic S.R.L.
- Molecules for controlling autoimmune response18 Jun 2026US 2026/0167684 A1Merida Biosciences, Inc.
- Fcrn/antigen-binding molecules and methods of use4 Jun 2026US 2026/0152573 A1argenx BV
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998